AbCellera Biologics

AbCellera Biologics, Inc. engages in the development of therapeutic antibodies. It offers antibody discovery platform that searches, decodes and analyzes natural immune systems to find antibodies that can be developed to prevent and treat disease. The company was founded by Carl Lars G. Hensen, Kathleen Lisaingo, Kevin Heyries, Véronique Lecault and Daniel Da Costa on November 8, 2012 and is headquartered in Vancouver, Canada.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbCellera Biologics reports robust earnings and growth opportunities ahead

AbCellera Biologics demonstrated strong financials and growth in Q4 2022, with a focus on building an engine for antibody discovery and development.
The company's strategic approach to partnerships and contract negotiations provides flexibility and potential for increased value creation.
Despite challenges in decision-making and program advancement, AbCellera's business model and liquidity position position it well for future opportunities.

AbCellera Biologics (ABCL) reports solid Q1 performance and eyes strategic growth opportunities

AbCellera Biologics (ABCL) showcases a strong performance in Q1 2023, focusing on long-term value creation and strategic partnerships.
Despite challenges in revenue streams and resource allocation, the company's emphasis on technology development and program diversity bodes well for future growth.
Opportunities lie in expanding partnerships, leveraging advancements in cancer therapy, and driving innovation in drug development for sustained success.

AbCellera reports Q2 revenue growth, faces clinical development uncertainty

AbCellera Biologics reported mixed financial results for Q2 2023, with revenue growth but a net loss due to continued investments.
The company showcased strengths in patent defense, R&D capabilities, and partnerships, while facing challenges in clinical development uncertainty and financial performance.
Opportunities lie in global therapeutics discovery, liquidity strength, and collaboration with Eli Lilly for COVID-19 antibody development, positioning AbCellera for future growth.

AbCellera reports Q3 results, advances innovative therapies and partnerships

AbCellera Biologics reported mixed financial results in Q3 2023 but demonstrated commitment to advancing innovative therapies and strategic partnerships.
Strengths lie in promising assets, financial stability, innovative molecule design, and progress on development candidates, while challenges include profitability concerns and operational complexities.
Opportunities for growth include expanding the product pipeline, exploring novel treatments through partnerships, and optimizing therapies for improved patient outcomes and market positioning.
Overall, AbCellera's performance reflects a balance of financial stability, innovation, and strategic focus, with future updates poised to drive investor interest and market impact.

AbCellera Biologics reports Q1 performance, highlights partnerships and growth

AbCellera Biologics showcased strong performance in Q1 2024, with a focus on advancing internal programs, strategic partnerships, and technological innovations.
Despite financial challenges, the company's strengths lie in its robust pipeline, strong financial position, and promising partnerships with industry leaders.
Navigating challenges in profitability and market competition, AbCellera has significant opportunities to drive growth through partnerships, technological advancements, and market expansion.

AbCellera Biologics reports Q2 revenue growth and strategic partnerships

AbCellera Biologics' Q2 2024 performance reflects a strong financial position, progress in key programs, and strategic partnerships driving future growth.
While facing challenges in profitability and research fee reductions, the company's focus on innovation and partnerships presents opportunities for market expansion.
Overall, AbCellera's emphasis on internal pipeline development and strategic collaborations positions them well for long-term success in the biologics industry.

AbCellera Biologics reports Q3 loss but poised for clinical advancements

AbCellera Biologics is navigating its transition to a clinical stage biotech with promising programs and a strong financial position.
While facing challenges in managing R&D expenses and achieving profitability, the company's strategic moves and preparedness for clinical trials bode well for future growth.
Opportunities lie in further investments in development, advancing novel therapies, and leveraging its financial strength to capitalize on emerging opportunities.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

AbCellera Presents New Data on Further Development and Characterization of T-Cell Engager Platform at SITC 2022

AbCellera reported its Q3 earnings on November 8th, solidly beating estimates on both the top and bottom lines. The company, in the days before the release, indicated that Regeneron has advanced its first GCPR target into preclinical development, further validating its platform.

AbCellera Biologics: Q3 Commentary - Moving Up The Value Stack

AbCellera Biologics Inc (NASDAQ:ABCL ) Q3 2022 Earnings Conference Call November 8, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Carl Hansen - Chairman, Chief Executive Officer and President Andrew Booth - Chief Financial Officer Conference Call Participants Do Kim - Piper Sandler Gaurav Goparaju - Berenberg Capital Markets Stephen Willey - Stifel Financial Corp. Gary Nachman - BMO Capital Markets Antonia Borovina - Bloom Burton Operator Good afternoon. And welcome to AbCellera's Third Quarter 2022 Business Update Conference Call.

AbCellera Biologics Inc (ABCL) Q3 2022 Earnings Call Transcript

AbCellera Biologics Inc. (ABCL) delivered earnings and revenue surprises of -11.11% and 31.34%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

AbCellera Biologics Inc. (ABCL) Q3 Earnings Miss Estimates

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Reports Q3 2022 Business Results

AbCellera Reports Q3 2022 Business Results

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Present at Upcoming Investor Conferences in November

AbCellera to Present at Upcoming Investor Conferences in November

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera's First Program with Regeneron in Multi-Target Collaboration Advances into Late-Stage Preclinical Development

AbCellera's First Program with Regeneron in Multi-Target Collaboration Advances in Preclinical Development

AbCellera Biologics Inc. (ABCL) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

AbCellera Biologics Inc. (ABCL) Reports Next Week: Wall Street Expects Earnings Growth

The mean of analysts' price targets for AbCellera Biologics Inc. (ABCL) points to a 137.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Believe AbCellera Biologics Inc. (ABCL) Could Rally 138%: Here's is How to Trade

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022

AbCellera to Report Third Quarter 2022 Financial Results on November 8, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022

AbCellera Announces Presentation of Data from CD3 T-Cell Engager Platform at SITC 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic

AbCellera Launches Second Phase of Global Headquarters Expansion to Advance Capabilities for Bringing New Medicines from Target to the Clinic

AbCellera Biologics reported Q2 numbers that were not all that impressive; however, the news of the commercialization agreement its partner Lilly inked has driven shares to near YTD highs. The commercialization plan looks to provide AbCellera with continued non-dilutive funding to further build its now $1 billion cash war chest.

AbCellera Biologics: COVID Antibody Set To Provide Continued Funding

AbCellera (ABCL) recently announced its Q2 2022 business results. These are the details.

AbCellera Reports Q2 2022 Business Results

The contract drug developer's stock is finally shaking off the froth of its initial public offering.

Why AbCellera Biologics Rallied as Much as 24% on Wednesday

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q2 2022 Earnings Conference Call August 9, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and CEO Andrew Booth - CFO Conference Call Participants Tiago Fauth - Credit Suisse Puneet Souda - SVB Securities Stephen Willey - Stifel Gary Nachman - BMO Capital Markets Do Kim - Piper Sandler Antonia Borovina - Bloom Burton Operator Good afternoon and welcome to AbCellera Second Quarter 2022 Business Update and Conference Call. My name is Libya and I'll facilitate the audio portion of today's indirect broadcast.

AbCellera Biologics Inc. (ABCL) CEO Dr. Carl Hansen on Q2 2022 Results - Earnings Call Transcript

VANCOUVER, British Columbia & CAMBRIDGE, Mass.--(BUSINESS WIRE)---- $ABCL--AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

AbCellera and Atlas Venture Collaborate to Empower the Development of Impactful Medicines for Patients

AbCellera Biologics Inc. (ABCL) Earnings Expected to Grow: Should You Buy?

VANCOUVER, British Columbia & SAN FRANCISCO--(BUSINESS WIRE)---- $ABCL--AbCellera (Nasdaq: ABCL) and Versant Ventures today announced a multi-year collaboration to discover therapeutic antibodies for multiple targets selected by Versant's portfolio of biologics-focused biotechs. Versant and AbCellera already have enabled three of the firm's stealth-stage companies under previous partnerships. Under the terms of the deal, Versant portfolio companies will have rights to develop and commercialize the result

Versant Ventures Collaborates with AbCellera to Accelerate Drug Development for its Portfolio of Biotech Companies

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL--AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022

AbCellera to Report Second Quarter 2022 Financial Results on August 9, 2022

VANCOUVER, British Columbia--(BUSINESS WIRE)---- $ABCL #AbCellera--AbCellera (Nasdaq: ABCL) today announced that Eli Lilly and Company (Lilly) has entered into a modified purchase agreement with the U.S. government to supply an additional 150,000 doses of bebtelovimab, the second antibody developed through AbCellera's collaboration with Lilly, for approximately $275 million. The existing U.S. government supply of bebtelovimab, including the new purchase, is expected to meet present demand through late August 2022.

Lilly to Supply an Additional 150,000 Doses of AbCellera-Discovered Antibody, Bebtelovimab, to the U.S. Government in Ongoing Effort to Provide COVID-19 Treatment Options

AbCellera Biologics Inc. (ABCL) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

AbCellera Biologics Inc. (ABCL) Stock Jumps 9.3%: Will It Continue to Soar?

AbCellera stock has continued to struggle of late given the absolutely terrible sentiment in the biotech market, however the company's actual business is thriving under the surface. In the Q1 earnings call, the company highlighted both the internally developed T-Cell engager platform, along with the Empirico deal which provides the option to co-invest in programs.

AbCellera Biologics: Fully Funded, With New Opportunities And Massive Insider Buying

The company has a plan for life after COVID-19, though it pales in comparison.

Why AbCellera Biologics Is 10% Lower Today

AbCellera Biologics Inc. (NASDAQ:ABCL ) Q1 2022 Results Conference Call May 10, 2022 5:00 PM ET Company Participants Tryn Stimart - Chief Legal and Compliance Officer Dr. Carl Hansen - President and Chief Executive Officer Andrew Booth - Chief Financial Officer Conference Call Participants Tiago Fauth - Credit Suisse Puneet Souda - SVB Securities Stephen Willey - Stifel Gary Nachman - BMO Capital Markets Do Kim - Piper Sandler Antonia Borovina - Bloom Burton Operator Good afternoon and welcome to AbCellera First Quarter 2022 Financial Results Conference Call. My name is Amber and I'll facilitate the audio portion of today's indirect broadcast.

News for AbCellera Biologics Stock (ABCL)